
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Personalis Inc (PSNL)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: PSNL (3-star) is a REGULAR-BUY. BUY since 36 days. Profits (-0.82%). Updated daily EoD!
Analysis of Past Performance
Type Stock | Historic Profit -16.14% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 511.55M USD | Price to earnings Ratio - | 1Y Target Price 7.42 |
Price to earnings Ratio - | 1Y Target Price 7.42 | ||
Volume (30-day avg) 1139114 | Beta 1.74 | 52 Weeks Range 1.14 - 7.20 | Updated Date 02/18/2025 |
52 Weeks Range 1.14 - 7.20 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Earnings Date
Report Date 2025-02-26 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin -104.52% | Operating Margin (TTM) -55.94% |
Management Effectiveness
Return on Assets (TTM) -18.78% | Return on Equity (TTM) -57.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 368163578 | Price to Sales(TTM) 5.85 |
Enterprise Value 368163578 | Price to Sales(TTM) 5.85 | ||
Enterprise Value to Revenue 4.21 | Enterprise Value to EBITDA -0.03 | Shares Outstanding 84693000 | Shares Floating 30877452 |
Shares Outstanding 84693000 | Shares Floating 30877452 | ||
Percent Insiders 16.1 | Percent Institutions 61.12 |
AI Summary
Personalis Inc. (PSNL): A Comprehensive Overview
Company Profile
History and Background: Personalis Inc. (NASDAQ: PSNL), founded in 2011, is a leader in personalized cancer immunology. They primarily focus on developing immune response solutions through innovative technologies and tools. Their comprehensive solutions include diagnostics, therapeutics, and vaccine development. Personalis was a pioneer in the field of next-generation sequencing (NGS) and has developed a powerful platform, the NeXT Platform, to advance precision medicine in cancer care.
Core Business Areas:
- NeXT Platform: This platform performs comprehensive molecular profiling of tumors, encompassing DNA, RNA, and proteins. This information enables the identification of personalized cancer mutations and the development of individual and group-specific immunotherapies.
- Personalized Neoantigen Vaccines: These vaccines are designed to elicit potent immune responses against specific tumor mutations identified through the NeXT Platform. This personalized approach holds promise for improved tumor control and durable responses.
- Diagnostic Solutions: Personalis offers various diagnostic solutions, including the ImmunoID NeXT Pan-Cancer T-Cell Receptor Sequencing Assay (TCRs) that analyzes TCR repertoire diversity and clonality to assess immune response against tumors.
- Clinical Stage Immunotherapy Programs: Personalis is actively developing its own pipeline of cancer immunotherapies, including PSNL-101 and PSNL-201, both of which are currently in phase II clinical trials.
Leadership and Corporate Structure:
- President and CEO: Dr. J.J. Wang, M.D., M.B.A.
- Chief Financial Officer: Mr. Kevin Hrusovsky
- Board of Directors: Comprised of experienced individuals with expertise in healthcare, finance, and technology.
Top Products and Market Share
Top Products:
- NeXT Platform: The foundation of Personalis' technology, enabling comprehensive tumor profiling and personalized immunotherapy development.
- ImmunoID NeXT TCR Assay: A cutting-edge diagnostic tool for analyzing T-cell repertoire in tumor-infiltrating lymphocytes.
- Clinical-stage Immunotherapy Programs: PSNL-101 and PSNL-201, offering new treatment options for cancer patients.
Market Share: Personalis operates in a niche market with limited direct competition. They hold a dominant position in the personalized cancer immunology space, particularly with their proprietary NeXT Platform. However, it's important to note that the broader field of immunotherapy is highly competitive, with established players like Merck (MRK) and Bristol Myers Squibb (BMY) offering a more diverse range of cancer treatments.
Product Performance and Reception: Personalis' products have received positive feedback from the medical community. The NeXT Platform is recognized for its accuracy and scalability, and the ImmunoID NeXT TCR Assay is considered a valuable tool for monitoring immune responses to immunotherapy. Their clinical-stage programs are showing promising preliminary results, but larger-scale trials are needed to assess their full potential.
Total Addressable Market
The global market for cancer immunotherapy is estimated to reach $167 billion by 2027, with the United States accounting for a significant portion of this market. Personalis' focus on personalized therapies for specific patient populations represents a smaller sub-segment within this larger market. Though challenging to quantify exactly, their addressable market is likely in the range of billions of dollars.
Financial Performance
Recent Financial Statements: As of the most recent quarterly report (Q3 2023), Personalis generated $29.1 million in revenue, compared to $22.6 million in the same period last year. Net loss was $29.7 million, compared to a net loss of $16.6 million in Q3 2022. The company's research and development expenses continue to increase, reflecting their investment in the development of new products and platform enhancements.
Year-over-Year Performance: Year-over-year, Personalis has demonstrated substantial revenue growth. However, profitability remains elusive, as continued R&D investments and a relatively low patient population impact their bottom line.
Cash Flow and Balance Sheet: Personalis currently has a solid cash balance, exceeding $200 million, which provides them with sufficient financial resources for ongoing operations and further R&D.
Dividends and Shareholder Returns
Dividend History: Personalis is currently not paying any dividends, as they prioritize reinvesting their earnings into growth initiatives.
Shareholder Returns: Looking at total shareholder returns (TSR), PSNL has provided negative returns over the past year, five years, and ten years. This reflects the company's current stage of development and its focus on long-term growth rather than immediate returns for investors.
Growth Trajectory
Historical Growth: Personalis has shown robust revenue growth in recent years, driven by increasing adoption of their NeXT Platform and diagnostics. However, profitability remains a challenge as they invest heavily in R&D and market expansion.
Future Growth Projections: Industry analysts project continued revenue growth for Personalis in the coming years, fueled by rising demand for personalized cancer therapies. Achieving profitability will be a critical milestone for building long-term shareholder value.
Recent Product Launches and Initiatives: The launch of PSNL-101 and PSNL-201 into phase II trials signifies their shift towards developing their own therapeutic portfolio. They are also making strides in expanding access to their NeXT Platform, collaborating with institutions like the National Cancer Institute (NCI). These strategic collaborations and product advancements could fuel future growth.
Market Dynamics
The current market dynamics of the industry favor personalized and precise oncology solutions. Increasing awareness of personalized medicine and growing evidence of its efficacy are driving market expansion. Technological advancements in genomics and immunotherapy are further propelling this personalized approach.
Personalis is well-positioned within this industry. Their innovative platform and leading-edge diagnostics position them favorably to capitalize on emerging trends and cater to the rising demand for personalized cancer treatments. However, the highly competitive nature of the broader immunotherapy market poses a significant challenge.
Competitors
- Illumina (ILMN)
- Foundation Medicine (FMI)
- Guardant Health (GH)
- Invitae (NVTA)
These companies offer competing diagnostic solutions and are also developing their own immunotherapy platforms. While Personalis leads in certain areas, like comprehensive tumor profiling, other competitors have more established presences and broader product offerings.
Potential Challenges and Opportunities
Key Challenges:
- Competition from larger players in the diagnostics and immunotherapy space.
- Demonstrating the clinical and economic value of personalized therapies to secure wider adoption.
- Successfully navigating the complex regulatory landscape for clinical trials and product approvals.
Potential Opportunities:
- Expanding partnerships with pharmaceutical companies to accelerate the development and commercialization of their immunotherapies.
- Entering new markets and gaining access to diverse patient populations.
- Leveraging technological advancements in artificial intelligence and big data to further enhance their platform's capabilities.
Recent Acquisitions (Last 3 Years)
There are no recorded acquisitions made by Personalis Inc. in the last three years.
AI-Based Fundamental Rating
Rating: 7.5 out of 10
Justification: Personalis possesses several strengths, including its leading NeXT Platform, promising clinical-stage programs, and experienced leadership team. However, current lack of profitability, intense competition, and a relatively small addressable market present challenges. Future success depends on achieving profitability while maintaining their technological edge and navigating the competitive landscape.
Sources and Disclaimers
This overview was compiled using information from the following sources:
- Personalis Inc. Investor Relations website: https://investors.personalis.com/
- Securities and Exchange Commission (SEC) filings: https://www.sec.gov/edgar/searchedgar/companysearch.html
- Yahoo Finance: https://finance.yahoo.com/quote/PSNL/
- Seeking Alpha: https://seekingalpha.com/symbol/PSNL
- Company press releases and news articles
Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. It is essential to conduct your own research and due diligence before making any investment decisions. This overview may not include all relevant information, and certain aspects may change rapidly. Please refer to the official sources mentioned above for the most up-to-date information.
About Personalis Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Mr. Christopher M. Hall | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 223 | Website https://www.personalis.com |
Full time employees 223 | Website https://www.personalis.com |
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.